Singapore, May 5, 2008: Canada-based QSV Biologics, an international cGMP biologics contract manufacturer providing microbial fermentation and cell culture, and purification services, has been awarded a cGMP manufacturing contract for a recombinant protein under development by Pfizer. The protein will be manufactured at QSV's Edmonton facility and is intended for clinical trials. Work on the project is to begin immediately, and will include technology transfer, scale-up and cGMP manufacturing.

 

Dr Graeme Macaloney, Founder, President & CEO of QSV said, "The execution of this contract is the culmination of extended evaluations by the Pfizer organization, reflecting QSV's continuing dedication to quality, speed and value. This project is an extremely good fit for our capabilities and indicative of our ability to respond to the challenging requirements of respected companies like Pfizer."

 

Dr Rick Rutter, Vice President of Global Biologics in the Pharmaceutical Sciences division of Pfizer Global Research and Development said, "Speed to clinic is of great importance for early development candidates and QSV has a record of delivering quality product on-time and on-budget. QSV will play a supporting role in realizing Pfizer's vision of becoming a top tier biotherapeutic company."